Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABL501 in Advanced Solid Tumors
NCT05101109Phase 1Completed
- Sponsor
- ABL Bio
- Start
- Oct 2021
- Primary completion
- May 2024
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ABL501 in solid tumor, sponsored by ABL Bio. Primary endpoints: Dose-Limiting Toxicities, Treatment-Emergent Adverse Events, Serious Adverse Events, Immune-Related Adverse Events, Infusion-Related Reactions up to 24 months and 1 more. Started Oct 2021; status: completed.
02
Drugs
ABL501
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05101109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05101109.